Özet:

HEMOVIJILANCE is a series of monitoring procedures that cover the entire transmission chain from the collection and processing of blood and blood components to the recipient to the transfusion and tracking, with the aim of collecting, evaluating and preventing the recurrence of information about unwanted events and reactions. One of the main objectives of the development of the hemovigilance program is to improve the reports of unwanted reactions related to transfusion. In our study, we aimed at identifying the frequency of unwanted reactions related to transfusion developing in patients in our hospital that provides 3rd stage health care and contributing to national hemovigilance data. NEED AND METHODS: Our study assessed the unwanted reactions related to transfusions of all blood/blood products performed between 1 January 2013 and 31 December 2019 at the University of Muğla Sıtkı Koçman Education and Research Hospital. Transfusion reactions included in the study under the guidance of the International Association for Blood Transfusion Hemovigilancy Working Group "Standard Identification Recommendations for the Monitoring of Non-Infectious Non-Demand Transfusion Reactions" were categorized. A total of 106,355 blood and blood components transfusion records were evaluated during the study period. The distribution of the blood components used was determined as 68866 (%64.7) erythrosite concentration, 28083 (%26.4) fresh frozen plasma, 5664 (%5.3) swimming thrombocite concentration, 3465 (%3.2) aferez thrombocite concentration, 114 (%0.1) full blood, 163 (%0.1) cryopresipitat. A total of 82 unwanted reactions associated with transfusions were, and the association rate of all reactions was between 1-3 probability levels. All the unwanted reactions were acute and no report of delayed reactions. There was no transfusion reaction that caused death. 61% of patients developing the reaction were female (n=50) and 39% (n=32) male. The age of the cases varies between 8 months and 83 years of age, with an average of 34.63±23.6. A statistically significant difference has been found between the incidence rates of reactions in the events according to the years (p=0,042; p<0,05). The transfusion of blood/blood product is an inevitable method of treatment in order to prevent mortality in life-threatening diseases. With the aim of protecting this inevitable treatment from complications affecting morbidity and mortality, interest in hemovigilance programs is increasing worldwide. For this purpose, all countries are creating national hemovigilance programs. However, especially the clinical doctors should consider attracting attention to these programs as the main goal of reducing complications.

Anahtar Kelimeler: